Jing-Yi Chern
Overview
Explore the profile of Jing-Yi Chern including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
111
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alqaisi H, Cohn D, Chern J, Duska L, Jewell A, Corr B, et al.
Clin Cancer Res
. 2025 Jan;
PMID: 39836408
Purpose: Mesothelin (MSLN) is highly expressed in high grade serous/ endometrioid ovarian cancers (HGOC). Anetumab ravtansine (AR) is an antibody drug conjugate directed at MSLN antigen with a tubulin polymerization...
2.
Yang M, Martinez U, Fulton H, Maconi M, Turner K, Powell S, et al.
Support Care Cancer
. 2023 Jul;
31(8):483.
PMID: 37480364
Background: Promoting smoking cessation is recognized as an essential part of cancer care. Moffitt Cancer Center, supported by the National Cancer Institute Cancer Moonshot Cancer Center Cessation Initiative, developed and...
3.
Martin A, Colin-Leitzinger C, Sinha S, Chern J, Peres L
Br J Cancer
. 2023 Apr;
128(12):2236-2242.
PMID: 37024666
Background: The study objective is to examine the impact of obesity on frontline carboplatin dosing in the neoadjuvant and adjuvant settings and to evaluate the association of dosing with survival...
4.
Wang T, Read S, Moino D, Ayoubi Y, Chern J, Tworoger S
Cancer Epidemiol Biomarkers Prev
. 2022 Jul;
31(7):1376-1382.
PMID: 35775222
Background: Little is known about the influence of smoking on ovarian cancer survival. We investigated this relationship in a hospital-based study. Methods: Analyses included 519 women with ovarian cancer. We...
5.
Martin A, Sinha S, Peres L, Hakam A, Chon H, Hoffman M, et al.
Gynecol Oncol
. 2022 Apr;
165(3):514-521.
PMID: 35487774
Objective: To determine the effect of distance to closest negative margin on survival after pelvic exenteration (PE). Methods: In this retrospective analysis of PE at Moffitt Cancer Center from 2000...
6.
Karpel H, Chern J, Smith J M, Smith A J, Pothuri B
Gynecol Oncol
. 2022 Apr;
165(3):546-551.
PMID: 35483985
Objectives: Patients with germline mutations in mismatch repair genes (MLH1, MSH2, MSH6, PMS2) associated with Lynch syndrome (LS) have an increased lifetime risk of endometrial cancer (EC). Multi-gene panel testing...
7.
Martin A, Wells A, Anderson M, Chern J, Rutherford T, Shahzad M, et al.
Gynecol Oncol
. 2021 Oct;
163(3):552-556.
PMID: 34674890
Objective: To describe the incidence, complications, and trends associated with ureteral surgeries on a gynecologic oncology service in the context of a fellowship training program over a 24-year period. Methods:...
8.
Lee S, Chern J, Frey M, Comfort A, Lee J, Roselli N, et al.
Gynecol Oncol Rep
. 2021 Oct;
38:100862.
PMID: 34621945
Objective: To compare perioperative outcomes of the elderly versus non-elderly patients on ERPs undergoing laparotomy for gynecologic surgery. Methods: From January 2016 to June 2017, patients undergoing elective laparotomies for...
9.
Asamoah F, Yarney J, Scott A, Vanderpuye V, Yuan Z, Fernandez D, et al.
JCO Glob Oncol
. 2020 Oct;
6:1510-1518.
PMID: 33021855
Purpose: Cervical cancer remains a major health challenge in low- to middle-income countries. We present the experiences of two centers practicing in variable resource environments to determine predictors of improved...
10.
Rishi A, Rollins M, Ahmed K, Hunt D, Sarkar P, Fernandez D, et al.
Gynecol Oncol
. 2019 Nov;
156(2):349-356.
PMID: 31771865
Introduction: To evaluate clinical outcomes, pattern of failure, and toxicity after high-dose intensity-modulated radiation therapy (IMRT) for advanced vulvar cancer. Methods: In this IRB approved retrospective study, the charts of...